Mon, January 10, 2022
Sun, January 9, 2022
Fri, January 7, 2022
Thu, January 6, 2022
Wed, January 5, 2022
Tue, January 4, 2022
Mon, January 3, 2022
Sun, January 2, 2022
Fri, December 31, 2021
Thu, December 30, 2021
Wed, December 29, 2021
Tue, December 28, 2021
Mon, December 27, 2021
Thu, December 23, 2021
Wed, December 22, 2021

Gil Blum Maintained (SRPT) at Strong Buy with Decreased Target to $150 on, Jan 5th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-150-on-jan-5th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $157 to $150 on, Jan 5th, 2022.

Gil has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 1 agrees with Gil's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021


These are the ratings of the 5 analyists that currently disagree with Gil


  • Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $125 on, Thursday, December 9th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $145 on, Thursday, November 4th, 2021
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021

Publication Contributing Sources